New Findings Show Anti-Tumor Activity Of KEYTRUDA - Quick Facts

(RTTNews) - MSD, known as Merck (MRK) in the United States and Canada, announced the first-time presentation of findings investigating the use of KEYTRUDA, the company's anti-PD-1 therapy, as a monotherapy in patients with advanced unresectable nasopharyngeal carcinoma or NPC - a type of head and neck cancer - whose tumors express PD-L1.

The company said that data were from a Phase 1b study and showed an overall response rate or ORR of 22.2 percent in evaluable patients who were treated with KEYTRUDA.

MSD has initiated a comprehensive clinical development program evaluating KEYTRUDA in head and neck cancer across multiple lines of therapy as monotherapy and in combination with chemotherapy as well as other agents.